| Literature DB >> 29178841 |
Xin Yang1, Suyun Qian2, Kaihu Yao3, Lijuan Wang1, Yingchao Liu1, Fang Dong4, Wenqi Song4, Jinghui Zhen4, Wei Zhou4, Hong Xu4, Hongyan Zheng4, Wenting Li3.
Abstract
BACKGROUND: This study aimed to investigate the clinical and molecular epidemiology and biofilm formation of Staphylococcus aureus (SA) isolated from pediatricians in China.Entities:
Keywords: Antimicrobial resistance; Biofilm; China; Clonal lineage; Pediatrician; Staphylococcus aureus
Mesh:
Substances:
Year: 2017 PMID: 29178841 PMCID: PMC5702180 DOI: 10.1186/s12879-017-2833-7
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Pathogen and patient characteristics
| Characteristics | Total | MRSA | MSSA |
|
|---|---|---|---|---|
| Patients | 104 | 60 | 44 | |
| Patient characteristics | ||||
| Female sex, n (%) | 41 (39.4) | 28 (46.7) | 13 (29.5) | 0.1044 |
| Age (months), median (IQRa) | 5.2 (49.6) | 3.9 (57.5) | 8.3 (49.4) | 0.424 |
| Age distribution | 0.7883 | |||
| ≤ 28 day | 31 (29.8) | 20 (33.3) | 11 (25.0) | |
| 29 day-3 years | 46 (44.2) | 25 (41.7) | 21 (47.7) | |
| 4–6 years | 10 (9.6) | 5 (8.3) | 5 (11.4) | |
| 7–15 years | 17 (16.4) | 10 (16.7) | 7 (15.9) | |
| Origin | 1.000 | |||
| Community associated | 57 (54.8) | 33 (55.0) | 24 (54.5) | |
| Hospital associated | 47 (45.2) | 27 (45.0) | 20 (45.5) | |
| Disease | 0.0031 | |||
| Skin and soft tissue infection | 37 (35.58) | 28 (46.7) | 9 (20.5) | |
| Pneumonia | 44 (42.3) | 24 (40.0) | 20 (45.5) | |
| Bloodstream infection | 21 (20.2) | 6 (10.0) | 15 (34.1) | |
| Bone and joint infection | 2 (1.9) | 2 (3.3) | 0 | |
| Laboratory examination | ||||
| White cell count-Median (IQR) (109/L) | 13.7 (9.88) | 13.9 (8.7) | 13.3 (12.4) | 0.5834 |
| Neutrophil count-Median (IQR) (109/L) | 7.9 (10.74) | 8.7 (10.4) | 7.2 (11.9) | 0.7365 |
| Neutrophils percentage-Median (IQR) | 61.6 (33.3) | 62.1 (30.0) | 60.9 (36.8) | 0.7107 |
| C-reactive protein-Median (IQR) (mg/L) | 18.5 (51.5) | 14.0 (66.0) | 24.0 (50.0) | 0.8506 |
| Co-infectionb | 34.0 (32.7) | 18.0 (30.0) | 16 (36.4) | 0.5308 |
| Hospitalization | ||||
| Hospital days-median (IQR) | 13 (11.0) | 12 (10) | 13 (10.8) | 0.9056 |
| Intensive care unit (ICU) admission | 26 (25.0) | 12 (20.0) | 14 (31.8) | 0.1789 |
| MLST | <0.0001 | |||
| 5 | 5 (4.8) | 0 | 5 (11.4) | |
| 6 | 5 (4.8) | 1 (1.7) | 4 (9.1) | |
| 7 | 4 (3.8) | 0 | 4 (9.1) | |
| 22 | 11 (10.6) | 2 (3.3) | 9 (20.5) | |
| 25 | 4 (3.8) | 0 | 5 (11.4) | |
| 59 | 49 (47.1) | 46 (76.7) | 3 (6.8) | |
| 188 | 4 (3.8) | 0 | 4 (9.1) | |
| 398 | 5 (4.8) | 0 | 5 (11.4) | |
| Othersc | 17 (16.3) | 11 (18.3) | 6 (13.6) | |
|
| <0.0001 | |||
| t002 | 4 (3.8) | 0 | 4 (9.1) | |
| t189 | 4 (3.8) | 0 | 4 (9.1) | |
| t309 | 12 (11.5) | 3 (5.0) | 9 (20.5) | |
| t437 | 41 (39.4) | 39 (65.0) | 2 (4.5) | |
| t441 | 4 (3.8) | 4 (6.7) | 0 | |
| t701 | 4 (3.8) | 0 | 4 (9.1) | |
| Othersd | 35 (33.7) | 14 (23.3) | 30 (68.2) | |
| SCC | / | |||
| IV | 51 (85.0) | 51 (85.0) | / | |
| V | 6 (10.0) | 6 (10.0) | / | |
| NTe | 3 (5.0) | 3 (5.0) | / | |
aIQR, interquartile range
bIncluding bacteria (Pertussis, Acinetobacter baumanii, Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Mycobacterium Tuberculosis, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Enterobacter cloacae), fungus (Candida albicans, Candida krusei), virus (Respiratory syncytial virus, Influenza A virus, Adenovirus, Cytomegalovirus) and Mycoplasma pneumoniae
cThe other MLSTs were ST1 (1 isolate), ST30 (1 isolate), ST97 (1 isolate), ST121 (1 isolate), ST338 (2 isolates), ST896 (1 isolate), ST1224 (1 isolate), ST1821 (1 isolate) in the MRSA group, and ST1 (1 isolate), ST15 (3 isolates), ST121 (1 isolate), ST950 (1 isolate) in the MSSA group
dThe other spa types were t021 (1 isolate), t114 (3 isolates), t163 (1 isolate), t172 (2 isolates), t267 (1 isolate), t1751 (1 isolate), t3515 (1 isolate), t3590 (1 isolate), t4549 (1 isolate), t8860 (1 isolate), t12946 (1 isolate) in the MRSA group, and t034 (2 isolates), t078 (2 isolates), t084 (3 isolates), t091 (2 isolates), t127 (1 isolate), t163 (1 isolate), t167 (1 isolate), t310 (1 isolate), t571 (3 isolates), t660 (1 isolate), t796 (1 isolate), t1062 (1 isolate), t1818 (1 isolate), t2092 (1 isolate) in the MSSA group
eNontypable
Fig. 1The modes of acquisition among different infections (a) and different age groups (b)
Fig. 2Prevalence of Staphylococcus aureus STs among different modes of acquisition. a Distribution of the STs among CA-MRSA and HA-MRSA isolates; b Distribution of the STs among CA-MSSA and HA-MSSA isolates
Non-susceptibility rates of different genotypes of SA in pediatric population in China
| Isolates (n) | PEN | CXM | ERY | CLI | TET | GEN | CHL | RIF | CIP | SXT | LZD | VAN | MUP | TGC | FUS | MDRa | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRSA | 60 | 96.7 | 38.4 | 100.0 | 83.3 | 40.0 | 5.0 | 63.3 | 3.3 | 20.0 | 0 | 0 | 0 | 0 | 0 | 1.7 | 76.7 |
| ST59-SCC | 37 | 97.3 | 45.9 | 100.0 | 91.9 | 54.1 | 2.7 | 70.3 | 2.7 | 18.9 | 0 | 0 | 0 | 0 | 0 | 0 | 83.8 |
| Others | 23 | 95.7 | 26.1 | 100.0 | 69.6 | 82.6 | 8.7 | 52.2 | 4.3 | 21.7 | 0 | 0 | 0 | 0 | 0 | 4.3 | 65.2 |
| MSSA | 44 | 95.5 | 0 | 100.0 | 31.8 | 18.2 | 25.0 | 61.4 | 0 | 13.6 | 0 | 0 | 0 | 0 | 0 | 0 | 77.3 |
| ST5-t002 | 4 | 75.0 | 0 | 100.0 | 75.0 | 25.0 | 75.0 | 50.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 75.0 |
| ST6-t701 | 4 | 100.0 | 0 | 100.0 | 0 | 0 | 0 | 75.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 75.0 |
| ST22-t309 | 8 | 100.0 | 0 | 100.0 | 12.5 | 12.5 | 0 | 37.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 62.5 |
| ST188-t189 | 4 | 100.0 | 0 | 100.0 | 25.0 | 25 | 25.0 | 75.0 | 0 | 25.0 | 0 | 0 | 0 | 0 | 0 | 0 | 75.0 |
| Others | 24 | 95.8 | 0 | 100.0 | 37.5 | 20.8 | 29.2 | 66.7 | 0 | 20.8 | 0 | 0 | 0 | 0 | 0 | 0 | 83.3 |
| Total | 104 | 96.2 | 22.1 | 100.0 | 61.5 | 30.8 | 13.4 | 62.5 | 1.9 | 17.3 | 0 | 0 | 0 | 0 | 0 | 0 | 85.6 |
|
| 1.000 | <0.0001 | – | <0.0001 | 0.0193 | 0.0069 | 0.8408 | 0.5071 | 0.4431 | – | – | – | – | – | 1.000 | 1.000 |
PEN Penicillin, CXM Cefuroxime, ERY Erythromycin, CLI Clindamycin, TET Tetracycline, GEN Gentamicin, CHL Chloramphenicol, CIP Ciprofloxacin, RIF Rifampin, SXT Trimethoprim-sulfamethoxazole, LNZ Linezolid, VAN Vancomycin, MUP Mupirocin, TGC Tigecycline, FA Fusidic acid
a MDR multi-drug resistance. MDR-MRSA, resistant to ≥ 3 classes of non-β-lactam antimicrobials; MDR-MSSA, resistant to ≥ 3 classes of antibiotics including β-lactam antibiotics
Biofilm formation ability of MRSA and MSSA regarding to different genotypes
| Genotype | Isolates (n) | WBF (n, %) | MBF (n, %) | SBF (n, %) | OD value (Median) |
|---|---|---|---|---|---|
| MRSA | 60 | 1 (1.67) | 9 (15.0) | 50 (83.3) | 0.68 |
| MLST type | |||||
| ST59 | 46 | 0 | 6 (13.0) | 40 (87.0) | 0.72 |
| Others | 14 | 1 (7.1) | 3 (21.4) | 10 (71.4) | 0.59 |
| SCC | |||||
| IV | 51 | 0 | 7 (13.7) | 44 (86.3) | 0.69 |
| V | 6 | 0 | 1 (16.7) | 5 (83.3) | 0.59 |
| NT* | 3 | 1 (33.3) | 1 (33.3) | 1 (33.3) | 0.22 |
|
| |||||
| t437 | 39 | 0 | 6 (15.4) | 33 (84.6) | 0.67 |
| Others | 21 | 1 (4.8) | 3 (14.3) | 17 (80.9) | 0.70 |
| Combined genotype | |||||
| ST59-SCC | 37 | 0 | 6 (16.2) | 31 (83.8) | 0.67 |
| Others | 23 | 1 (4.4) | 3 (13.0) | 19 (82.6) | 0.70 |
| MSSA | 44 | 2 (4.5) | 18 (40.9) | 24 (54.5) | 0.42 |
| MLST type | |||||
| 5 | 5 | 0 | 1 (20.0) | 4 (80.0) | 0.65 |
| 6 | 4 | 0 | 2 (50.0) | 2 (50.0) | 0.36 |
| 7 | 4 | 0 | 1 (25.0) | 3 (75.0) | 0.84 |
| 22 | 9 | 0 | 4 (44.4) | 5 (55.6) | 0.42 |
| 25 | 4 | 1 (25.0) | 2 (50.0) | 1 (25.0) | 0.26 |
| 188 | 4 | 0 | 0 | 4 (100.0) | 1.14 |
| 398 | 5 | 0 | 5 (100.0) | 0 | 0.34 |
| Others | 9 | 1 (11.1) | 3 (33.3) | 5 (55.6) | 0.49 |
|
| |||||
| t002 | 4 | 0 | 1 (25.0) | 3 (75.0) | 0.60 |
| t189 | 4 | 0 | 0 | 4 (100.0) | 1.1 |
| t309 | 9 | 0 | 5 | 4 | 0.36 |
| t701 | 4 | 0 | 2 (50.0) | 2 (50.0) | 0.36 |
| Others | 23 | 2 | 10 | 11 | 0.40 |
| Combined genotype | |||||
| ST5-t002 | 4 | 0 | 1 (25.0) | 3 (75.0) | 0.60 |
| ST6-t701 | 4 | 0 | 2 (50.0) | 2 (50.0) | 0.36 |
| ST22-t309 | 8 | 0 | 4 (50.0) | 4 (50.0) | 0.37 |
| ST188-t189 | 4 | 0 | 0 | 4 (100.0) | 1.1 |
| Others | 24 | 2 (8.7) | 11 (45.8) | 11 (45.8) | 0.38 |
*Nontypable
Fig. 3Biofilm formation assays of Staphylococcus aureus. a Comparison of the biofilm formation ability between MRSA and MSSA isolates. b Comparison of the biofilm formation ability of common genotypes. c Biofilm formation ability of Staphylococcus aureus isolated from pediatricians with different infections
The prevalence of biofilm associated genes among MRSA and MSSA clinical isolates
| Comined genotype | Isolates(n) |
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRSA | 60 | 100.0 | 98.3 | 100.0 | 3.3 | 100.0 | 100.0 | 10.0 | 1.7 | 85.0 | 76.7 | 20.0 | 91.7 |
| ST59-SCC | 37 | 100.0 | 97.3 | 100.0 | 0 | 100.0 | 100.0 | 2.7 | 0 | 88.5 | 78.4 | 5.4 | 94.5 |
| Others | 23 | 100.0 | 100.0 | 100.0 | 8.7 | 100.0 | 100.0 | 21.7 | 4.4 | 82.6 | 73.9 | 43.5 | 87.0 |
| MSSA | 44 | 100.0 | 100.0 | 86.4 | 27.3 | 100.0 | 100.0 | 52.3 | 9.1 | 95.5 | 77.3 | 75.0 | 79.5 |
| ST5-t002 | 4 | 100.0 | 100.0 | 100.0 | 0 | 100.0 | 100.0 | 0 | 0 | 75.0 | 100.0 | 100.0 | 100.0 |
| ST6-t701 | 4 | 100.0 | 100.0 | 100.0 | 0 | 100.0 | 100.0 | 100.0 | 0 | 100.0 | 100.0 | 75.0 | 75.0 |
| ST22-t309 | 8 | 100.0 | 100.0 | 25.0 | 0 | 100.0 | 100.0 | 75.0 | 0 | 100.0 | 87.5 | 87.5 | 87.5 |
| ST188-t189 | 4 | 100.0 | 100.0 | 100.0 | 0 | 100.0 | 100.0 | 100.0 | 0 | 100.0 | 100.0 | 50.0 | 75.0 |
| Others | 24 | 100.0 | 100.0 | 100.0 | 50.0 | 100.0 | 100.0 | 37.5 | 16.67 | 95.83 | 62.5 | 70.8 | 75.0 |
| Total | 104 | 100.0 | 99.0 | 94.23 | 13.5 | 100.0 | 100.0 | 27..9 | 4.8 | 89.4 | 76.9 | 43.3 | 86.5 |
|
| – | 1.000 | 0.0047 | 0.0007 | – | – | <0.0001 | 0.1598 | 0.1126 | 1.000 | <0.0001 | 0.9810 |
*Comparison between MRSA and MSSA isolates